Introduction {#s1}
============

The rapid expansion of combination antiretroviral treatment (cART) has dramatically improved the prognosis of patients infected with HIV and decreased HIV/AIDS associated morbidity and mortality [@pone.0088305-Staszewski1]--[@pone.0088305-Borrell1]. Since year 2000, most developing countries have initiated cART treatment programs, many of which were scaled-up in 2003 through the "3 by 5" initiative. At the end of 2011, more than 8 million people in low- and middle-income countries were receiving antiretroviral therapy (ART), up from 6.6 million in 2010 which represented an increase of about 20% [@pone.0088305-Joint1].

Since the China's National Free Antiretroviral Treatment Program (NFATP) began in 2002, cART use has scaled up rapidly. By the end of 2012, more than 208,216 patients across the country had received free antiretroviral treatment [@pone.0088305-Chinese1]. Many studies found that the NFATP has successfully increased life expectancy and reduced mortality among Chinese HIV patients [@pone.0088305-Zhang1]--[@pone.0088305-Liao1]. However, although rapid cART scale-up significantly decreased AIDS-related morbidity and mortality, HIV antiretroviral treatment programs are facing the challenge of potential widespread emergence and transmission of HIV drug resistance (HIVDR) [@pone.0088305-Liao1]--[@pone.0088305-Liao2].

In 2004, The World Health Organization (WHO), in collaboration with the United States Centers for Disease Control and Prevention (CDC) and through HIVResNet developed a global strategy for the assessment and prevention of HIVDR. The protocol for population-based surveillance of acquired HIVDR at sentinel ART clinics is designed to be used particularly in resource-limited countries, where decisions on ART regimens for a given patient population are made through monitoring HIVDR emergence during treatment in addition to related program factors [@pone.0088305-Protocol1]. In China, based on the WHO HIVDR surveys under the direction of the Ministry of Health HIVDR working group, studies have shown that community-based ART had significant effects on viral suppression and acquired HIVDR at six sentinel sites in China [@pone.0088305-Wang2]--[@pone.0088305-Ruan1]. However, the NFATP's first-line antiretroviral regimens have since been changed to exclude the use of didanosine (DDI) and to include the use of lamivudine (3TC) for all new patients initiating treatment [@pone.0088305-Manual1]. Due to these changes and the rapid scale-up of ART in China, the aim of this prospective survey study is to evaluate HIVDR in a cohort of Chinese HIV patients recently initiating 3TC-based first-line ART at four sentinel sites in 2011--2012.

Methods {#s2}
=======

Study Design and Study Participants {#s2a}
-----------------------------------

The four sentinel surveys were conducted in urban areas of China, including Jiangsu province (Nanjing, Suzhou, and Nantong cities), Guizhou province (Guiyang, Tongren, and Dujun cities), Hunan province (Hengyang City) and Chongqing Municipality (Shapingba, Jiulongpo, and Yuzhong districts), respectively, where most of HIV infection were transmitted through heterosexual intercourse and homosexual intercourse [@pone.0088305-Chinese1]. The survey was a prospective cohort study with follow-up at 12 months. The study subjects were recruited through sequential sampling at each clinic to participate in a one-year prospective cohort study. Criteria for enrolling in the study were: previously antiretroviral naive, 18 years or older, agreeing to initiate ART in the NFATP, and willing to provide informed consent. A baseline screening survey was conducted in 2011. The national treatment criterion at that time was: (1) CD4 cell count\<350/mm^3^; (2) World Health Organization (WHO) stage III/IV diseases, or (3) willingness to receive ART, regardless of the criteria 1 and 2. The ART regimen will be provided through the NFATP. First-line ART regimen consisted of tenofovir (TDF) or azidothymidine (AZT)+lamivudine (3TC)+efavirenz (EFV) or nevirapine(NVP) [@pone.0088305-Manual1]. The main study outcome was HIVDR emergence after the first year of ART. The specific objectives were to: (1) estimate the proportion of HIV RNA suppression to \<1000 copies/ml and associated factors at 12 months after starting first-line ART; and (2) identify the prevalence of specific HIVDR mutations among those with viral load ≥1000 copies/ml [@pone.0088305-Protocol1].

Ethics Statement {#s2b}
----------------

The study was approved by the institutional review board of the National Center for AIDS/STD Control and Prevention of the China Center for Disease Control and Prevention (NCAIDS, China CDC).

Data Collection {#s2c}
---------------

Data were collected using an interviewer-administered questionnaire. Each study participant was assigned a confidential identification number used to label questionnaires and blood specimens. The questionnaire was administered by trained interviewers in a private room. Questionnaires included demographic data, ART treatment and self-reported adherence data. Demographic variables included age, sex, ethnicity, education level, marital status, occupation and HIV transmission route. ART treatment variables included WHO clinical stage, initial regimen, ART distribution institution, ART refill interval, missed ART doses in the past month, ratio of on-time drug intake in the past month, and reasons for loss of treatment retention.

Laboratory Tests {#s2d}
----------------

All subjects provided blood specimens for testing CD4^+^ T-lymphocyte count (CD4 count), HIV viral load, and HIV drug resistance mutations at baseline and 12-month follow-up. CD4 count was tested using flow cytometry (FACSC Calibur, BD Company, USA) within 24 hours after specimen collection in local CDCs. Blood plasma was isolated and stored frozen at −80°C at local CDCs before transferring to NCAIDS in Beijing for testing viral load and drug resistance mutations. Plasma HIV RNA was quantified with real-time NASBA (NucliSense Easy Q, bioMérieux, France) or with COBAS (Roche Applied Biosystems, Germany) according to the manufacturers' recommendations. For the WHO surveys, successful viral suppression was defined as HIV RNA level \<1,000 copies/ml using a quality-assured viral load assay. In samples with viral load ≥1000 copies/ml, HIV drug resistance genotyping was performed at the WHO Accreditation Laboratory of NCAIDS, China CDC by using an in-house method as previously described [@pone.0088305-Wang2]--[@pone.0088305-Ruan1]. Drug resistance mutation analysis and viral subtype determination were performed on a 1.3 kb section of the HIV *pol* gene using the Stanford University HIV Drug Resistance Database online sequence analysis tool (<http://hivdb.stanford.edu/pages/algs/sierra_sequence.html>). We included mutation results that conferred low-, intermediate-, and high- level resistance [@pone.0088305-Shafer1]--[@pone.0088305-Zhong1].

Data Analysis {#s2e}
-------------

Questionnaire and laboratory data were double-entered and compared using EpiData software (The EpiData Association Odense, Denmark). Data were then converted and analyzed using Statistical Analysis System version 9.1 (SAS Institute Inc., Cary, NC, USA). The data were analyzed using unadjusted odds ratios with a test for significance according to chi-square test and Fisher's exact test. Variables that were significantly (p\<0.05) associated with HIV RNA \<1000 copies/ml at 12 months in the univariable analyses were considered for inclusion in the multivariable logistic regression model. Multivariable logistic regression was performed to examine the independent effect of each factor under consideration. All tests of significance were two-sided, with p-value \<0.05 indicating that an association was statistically significant.

Results {#s3}
=======

Demographic Characteristics {#s3a}
---------------------------

Among 535 consecutive participants enrolled, one was less than 18 years old, three refused to participate in the study, five did not receive national free regimen, and 13 patients with baseline HIVDR were excluded from this study. Thus, 513 subjects entered this prospective cohort and provided written informed consent. The baseline and 12-month follow-up characteristics were shown in [Table 1](#pone-0088305-t001){ref-type="table"}. Of 513 eligible patients, 139, 123, 119 and 132 participants were from Jiangsu, Guizhou, Hunan, Chongqing, respectively; 78.6% were male; the mean age were 38.8 years (SD, ±11.2 years); 90.1% belonged to the Han ethnic group; 47.0% had education level of junior high school or lower; 48.2% were infected through heterosexual intercourse; and the most common HIV viral subtype was CRF01_AE.

10.1371/journal.pone.0088305.t001

###### Characteristics of HIV patients receiving first-line ART in four sentinel antiretroviral treatment sites.

![](pone.0088305.t001){#pone-0088305-t001-1}

  Characteristics                                                        Jiangsu       Guizhou         Hunan       Chongqing         Total
  -------------------------------------------------------------------- ------------ -------------- ------------- -------------- ---------------
  Overall                                                                  139           123            119           132             513
  Age (mean ± SD, year)                                                 39.7±11.3      34.5±8.6      41.5±10.1     39.4±12.9       38.8±11.2
  Sex                                                                                                                           
  Male                                                                  121 (87.1)    85 (69.1)      86 (72.3)     111 (84.1)     403 (78.6)
  Female                                                                18 (12.9)     38 (30.9)      33 (27.7)     21 (15.9)      110 (21.4)
  Ethnicity                                                                                                                     
  Han                                                                   136 (97.8)    75 (61.0)     119(100.0)    132 (100.0)     462 (90.1)
  Other                                                                  3 (2.2)      48 (39.0)          0             0           51 (9.9)
  Education                                                                                                                     
  Junior high school or less                                            65 (46.8)     51 (41.5)      83(69.8)      42 (31.8)      241 (47.0)
  High school or more                                                   74 (53.2)     72 (58.5)      36(30.2)      90 (68.2)       272(53.0)
  Marital status                                                                                                                
  Married                                                               87 (62.6)     55 (44.7)      74 (62.2)     63 (47.7)      279 (54.4)
  Other                                                                 52 (37.4)     68 (55.3)      45 (37.8)     69 (52.3)      234 (45.6)
  Occupation                                                                                                                    
  Farmer                                                                16 (11.5)      7 (5.7)       21 (17.6)      3 (2.3)        47 (9.2)
  Other                                                                 123 (88.5)    116 (94.3)     98 (82.4)     129 (97.7)     466 (90.8)
  HIV transmission route                                                                                                        
  Heterosexual intercourse                                              67 (48.2)     60 (48.8)      71 (59.7)     49 (37.1)      247 (48.2)
  Homosexual intercourse                                                67 (48.2)     26 (21.1)       3 (2.5)      62 (47.0)      158 (30.8)
  Drug injection                                                            0         29 (23.6)      33 (27.7)      12 (9.1)       74 (14.4)
  Other                                                                  5 (3.6)       8 (6.5)       12 (10.1)      9 (6.8)        34 (6.6)
  HIV subtypes                                                                                                                  
  CRF01_AE                                                               90(64.7)      54(43.9)      88(74.0)       15(11.4)       247(48.1)
  CRF08_BC                                                                4(2.9)        3(2.4)        7(5.9)        11(8.3)         25(4.9)
  CRF07_BC                                                               24(17.3)      37(30.1)       7(5.9)        99(75.0)       167(32.6)
  Other                                                                  21(15.1)      29(23.6)      17(14.2)        7(5.3)        74(14.4)
  WHO clinic stage III or IV at baseline                                33 (23.7)     25 (20.3)     114 (95.8)     26 (19.7)      198 (38.6)
  HIV RNA \<1000 copies/mL at baseline                                   7 (5.0)      14 (11.4)       5 (4.2)       4 (3.0)        30 (5.9)
  CD4 count at baseline (cells/mm^3^)                                                                                           
  350 or above                                                           4 (2.9)       11 (8.9)          0         30 (22.7)       45 (8.8)
  200--349                                                              60 (43.1)     45 (36.6)      21 (17.6)     62 (47.0)      188 (36.7)
  100--199                                                              35 (25.2)     36 (29.3)      32 (26.9)     28 (21.2)      131 (25.5)
  0--99                                                                 40 (28.8)     31 (25.2)      66 (55.5)      12 (9.1)      149 (29.0)
  Initial ART regimen                                                                                                           
  AZT+3TC+NVP                                                           115 (82.7)    61 (49.6)      26 (21.9)     101 (76.5)     303 (59.1)
  D4T+3TC+NVP                                                            10 (7.2)      9 (7.3)       10 (8.4)       4 (3.0)        33 (6.4)
  AZT+3TC+EFV                                                            9 (6.5)      34 (27.7)      13 (10.9)     18 (13.7)       74 (14.4)
  D4T+3TC+EFV                                                            5 (3.6)      18 (14.6)      21 (17.7)      5 (3.8)        49 (9.5)
  3TC+TDF+EFV                                                               0             0          43(36.1)        4(3.0)         47(9.2)
  3TC+TDF+NVP                                                               0           1(0.8)        6(5.0)           0            7(1.4)
  Retention at 12-month follow-up study                                 128(92.1)     109(88.6)      94(79.0)      117(88.6)       448(87.3)
  Duration of follow-up (median, month)                                    12.1          12.1          12.1           11.9           12.0
  Reasons for not retained at 12 months                                                                                         
  Death                                                                  3 (2.2)       6 (4.9)       14 (11.8)      2 (1.5)        25 (4.9)
  Transferred out                                                           0             0           1 (0.8)          0            1 (0.2)
  Loss to follow-up                                                      1 (0.7)       6 (4.9)        8 (6.7)       10(7.6)        25 (4.9)
  Other                                                                  7 (5.0)       2 (1.6)        2(1.7)         3(2.3)        14 (2.7)
  Missed doses in the past month                                         12 (9.4)      10 (9.2)      26 (27.7)     15 (12.8)       63 (14.1)
  Ratio (95%) of on-time drug intake in the past month                  100 (78.1)    92 (84.4)      77 (81.9)     107 (91.5)     376 (83.9)
  On first-line ART at 12 months                                        127(99.2)     109(100.0)     90(95.7)      115(98.3)       441(98.4)
  HIV RNA \<1000 copies/ml at 12 months                                 113 (88.3)    102(93.6)      82 (87.2)     97 (82.9)      394 (87.9)
  HIV RNA \<500 copies/ml at 12 months                                  113(88.3)     102(93.6)      77(81.9)       86(73.5)       378(84.4)
  HIV RNA \<200 copies/ml at 12 months                                  113(88.3)     102(93.6)      76(80.9)       81(69.2)       372(83.0)
  HIVDR among HIV RNA ≥1000 copies/ml with PCR products at 12 months    3/12(25.0)   (1/5) (20.0)   (4/8)(50.0)   (3/15)(20.0)   (11/40)(27.5)

HAART Regimens and Immunologic Profiles {#s3b}
---------------------------------------

All patients received free standard first-line regimen through the NFATP, and 98.4% maintained the initial regimen at follow-up. Only 7(1.6%) patients switched to the second-line regimen during the follow-up. The initial ART regimen were AZT+3TC+NVP(59.1%), D4T+3TC+NVP(6.4%), AZT+3TC+EFV(14.4%), D4T+3TC+EFV(9.5%), 3TC+TDF+EFV(9.2%) and 3TC+TDF+NVP(1.4%). Among 65 participants who were lost to follow up, 4.9% had died, 4.9% were lost to contact, and 0.2% transferred out of the study districts ([Table 1](#pone-0088305-t001){ref-type="table"}).

Of the 448 patients retained at 12 month, CD4 cell count was 313 cells/mm^3^, which increased from the median 192 cells/mm^3^ at baseline(P\<0.0001). 14.1% reported missing doses, and 83.9% maintained ≥95% of on-time drug intake in the past month.

Genotypic Drug Resistance and Predictors for Viral Suppression Success {#s3c}
----------------------------------------------------------------------

After receiving ART for nearly one year, 394(87.9%) patients had plasma HIV RNA \<1000 copies/ml. Among the 54 samples with viral load ≥1000 copies/ml, 40 were successfully genotyped. Of the 11 with detectable HIVDR mutations, the proportion of drug resistance to NNRTIs, NRTIs and PIs were 100%, 81.8% and 0%, respectively. Among these, 9(81.8%) patients had multi-drug resistance to NNRTIs and NRTIs. The most common NNRTIs mutation site were K103N(36.4%), Y818C/I/V(27.3%) and K101E(18.2%). As well, M184V/I(72.7%), K65R(27.3%), D67N(27.3%) were found as the most frequent mutations to NRTIs ([Table 2](#pone-0088305-t002){ref-type="table"}).

10.1371/journal.pone.0088305.t002

###### HIV drug resistance and drug resistance mutations among the 11 patients with HIVDR mutations detected at 12 months at four sentinel antiretroviral treatment sites.

![](pone.0088305.t002){#pone-0088305-t002-2}

  Antiretroviral drug                                               N (%)      HIV drug resistance mutation, N (%)
  -------------------------------------------------------------- ------------ -------------------------------------
  Overall                                                         11 (100.0)  
  Non-nucleoside reverse transcriptase inhibitors (NNRTI, any)    11 (100.0)             K101E, 2 (18.2)
  Efavirenz (EFV)[\*](#nt101){ref-type="table-fn"}                11(100.0)              K103N, 4 (36.4)
  Nevirapine (NVP)[\*](#nt101){ref-type="table-fn"}               11 (100.0)             V106M, 1 (9.1)
  Delavirdine (DLV)                                               11 (100.0)           Y181C/I/V, 3 (27.3)
  Etravirine (ETV)                                                 6 (54.5)              Y188L, 2 (18.2)
  Rilpivirine (RPV)                                                8 (72.7)             G190A/Q, 2 (18.2)
                                                                                         M230L, 2(18.2)
  Nucleoside reverse transcriptase inhibitors (NRTI, any)          9 (81.8)   
  Lamivudine (3TC)[\*](#nt101){ref-type="table-fn"}                9 (81.8)              K65R, 3 (27.3)
  Azidothymidine (AZT)[\*](#nt101){ref-type="table-fn"}             0 (0)                D67N, 3 (27.3)
  Stavudine (D4T)[\*](#nt101){ref-type="table-fn"}                 3 (27.2)               V75L, 1 (9.1)
  Didanosine (DDI)[\*](#nt101){ref-type="table-fn"}                5 (45.5)               T69N, 1 (9.1)
  Abacavir (ABC)                                                   9 (81.8)             M184V/I, 8 (72.7)
  Emtricitabine (FTC)                                              9 (81.8)   
  Tenofovir (TDF) [\*](#nt101){ref-type="table-fn"}                4 (36.4)   
  Protease inhibitors+ (PI, any)                                   0 (0.0)    
  Multi-drug resistance to NNRTI and NRTI                          9(81.8)    

\*Provided through the National Free Antiretroviral Treatment Program (NFATP).

Protease inhibitors (PI):including ATV, DRV, FPV, IDV, LPV, NFV, SQV, and TPV.

The factors significantly associated with successful viral suppression at 12 month were analysed through univariable logistic regression ([Table 3](#pone-0088305-t003){ref-type="table"}). HIV transmission route, CD4 count at baseline, and missed doses in the past month were independent risk factors associated with virological failure (HIV RNA ≥1000 copies/ml). These three factors remained in the multivariable logistic regression model. Injecting drug use \[adjusted odds ratio (AOR) = 0.40,95% CI: 0.19,0.84; P = 0.0154\], CD4 count at baseline ≥350 cells/mm^3^(AOR = 0.32,95% CI: 0.14,0.72;P = 0.0056), and missed doses in the past month(AOR = 0.30,95% CI: 0.15,0.60;P = 0.0006) were negatively associated with virological success.

10.1371/journal.pone.0088305.t003

###### Factors associated with HIV RNA \<1000 copies/ml among HIV patients receiving first-line ART at 12 months in four sentinel antiretroviral treatment sites.
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  Variable                                                Number   HIV RNA \<1000copies/ml *N* (%)   Crude OR (95% CI)   *P-value*   Adjusted OR (95% CI)   *P-value*
  ------------------------------------------------------ -------- --------------------------------- ------------------- ----------- ---------------------- -----------
  Total                                                    448               394 (87.9)                                                                    
  Age (year)                                                                                                                                               
  ≤38                                                      196               174 (88.8)                                                                    
  \>38                                                     252               220 (87.3)               0.87(0.49,1.55)     0.6347                           
  Sex                                                                                                                                                      
  Male                                                     345               301 (87.3)                                                                    
  Female                                                   103                93 (90.3)              1.34 (0.66,2.81)     0.4066                           
  Ethnicity                                                                                                                                                
  Han                                                      403               352 (87.3)                                                                    
  Other                                                     45                42 (93.3)               2.03(0.61,6.79)     0.2510                           
  Education                                                                                                                                                
  Junior highschool or less                                204               174 (85.3)                                                                    
  High school or more                                      244               220 (90.2)              1.58 (0.89,2.80)     0.1170                           
  Marital status                                                                                                                                           
  Married                                                  248               219 (88.3)                                                                    
  Other                                                    200               175 (87.5)              0.93 (0.52,1.64)     0.7944                           
  Occupation                                                                                                                                               
  Other                                                    409               360 (88.0)                                                                    
  Farmer                                                    39                34 (87.2)              0.93 (0.35,2.48)     0.8777                           
  HIV transmission route                                                                                                                                   
  Other                                                    393               353 (89.8)                                                                    
  Drug injection                                            55                41 (74.5)              0.33 (0.17,0.66)     0.0017       0.40 (0.19,0.84)      0.0154
  WHO clinic stage at baseline                                                                                                                             
  I or II                                                  284               249 (87.7)                                                                    
  III or IV                                                164               145 (88.4)              1.07 (0.59,1.95)     0.8171                           
  HIV RNA at baseline                                                                                                                                      
  \<1000 copies/mL                                          28                26 (92.9)                                                                    
  ≥1000 copies/mL                                          420               368 (87.6)               0.54(0.13,2.36)     0.4166                           
  CD4 count at baseline (cells/mm^3^)                                                                                                                      
  0--349                                                   408               364 (89.2)                                                                    
  350 or above                                              40                30 (75.0)              0.36 (0.17,0.79)     0.0109       0.32 (0.14,0.72)      0.0056
  Initial ART regimen                                                                                                                                      
  3TC+TDF+NVP/EFV                                           40                34(85.0)                                                                     
  AZT+3TC+NVP/EFV                                          339               299 (88.2)              1.32 (0.52,3.33)     0.5585                           
  D4T+3TC+NVP/EFV                                           69                61 (88.4)               1.35(0.43,4.20)     0.6091                           
  Switched to second-line regimens                                                                                                                         
  No                                                       441                389(88.2)                                                                    
  Yes                                                       7                  5(71.4)                0.33(0.06,1.77)     0.1969                           
  ART distribution institution                                                                                                                             
  County hospital or CDC                                   377               334 (88.6)                                                                    
  Village clinic or township hospital                       71                60 (84.5)              0.70 (0.34,1.44)     0.3333                           
  Interval of ART refills                                                                                                                                  
  ≤90 days                                                 209               180 (86.1)                                                                    
  \>90 days                                                239               214 (89.5)              1.38 (0.78,2.44)     0.2694                           
  Missed doses in the past month                                                                                                                           
  No                                                       385               349 (90.7)                                                                    
  Yes                                                       63                45(71.4)               0.26 (0.14,0.49)    \<0.0001      0.30 (0.15,0.60)      0.0006
  Ratio (95%) of on-time drug intake in the past month                                                                                                     
  No                                                        72                44 (61.1)                                                                    
  Yes                                                      376                350(93.1)              8.57 (4.61,15.9)    \<0.0001                          
  Stopped the regimen in the past month                                                                                                                    
  No                                                       440                394(89.6)                                                                    
  Yes                                                       8                     0                       \<0.001         0.9814                           

Discussion {#s4}
==========

In this one-year prospective follow-up survey on HIVDR at sentinel sites in four Chinese provinces, viral load suppression (HIV RNA \<1000 copies/mL)was achieved at 12 months in 87.9% of treated patients, with a range from 82.9% to 93.6%. This demonstrated a rapid but successful scale up of China's NFATP. In the 2012 WHO drug resistance surveillance guideline, viral load suppression after 12 months of ART can be graded as poor (\<70%), fair (70--85%), or excellent (\>85%) [@pone.0088305-Protocol1]. All sentinel sites in our study met the excellent grade, and the overall suppression rate was comparable to treatment responses seen in other developing and developed countries [@pone.0088305-McMahon1]--[@pone.0088305-Fielding1]. As well, our previous surveillance studies in four and two sentinel sites in China showed that viral load suppression at 12 months was ≥70% and ≥85%, respectively [@pone.0088305-Wang2], [@pone.0088305-Ruan1]. Together, these HIVDR sentinel surveys indicated that virological failure did not increase over time during recent years of the NFATP's expansion, when approximately 50,000 ART-naïve HIV patients initiated treatment each year. Our findings also provide support to the argument that the current WHO target of \>70% viral load suppression at 12 months of treatment for low- and middle-income countries can be revised upwards, to such a rate as 85% [@pone.0088305-Protocol1].

The drug resistance mutations identified concurred with expected mutation patterns from a treatment program based on NNRTI and NRTI class drugs. Among patients with virological failure, 11 cases (27.5%) displayed NNRTI mutations and 9 cases (22.5%) displayed NRTI mutations. No protease inhibitor (PI) mutations were identified, which affirms that the continued use of PIs as second-line therapy is still viable in China. Our HIVDR results are comparable to reported values in other developed and developing countries [@pone.0088305-McMahon1]--[@pone.0088305-Fielding1].

Our study found that injecting drug use, baseline CD4 count ≥350, and missed doses in the past month were independently associated with virological failure (HIV RNA ≥1000 copies/ml) among HIV patients receiving free first-line ART in China. Virological failure as a result of poor adherence indicates that strengthening education and counseling among HIV patients should be an important priority for HIVDR prevention in China [@pone.0088305-Wang1], [@pone.0088305-Ma1]. Training for health care providers should also be improved, especially among those with fewer resources to new treatment technology. Another concern was the high proportion of virological failure among injection drug users (IDUs) [@pone.0088305-Wang2], [@pone.0088305-RodriguezArenas1]. Low uptake of MMT and needle exchange services and high syphilis incidence suggest that large numbers of IDUs engaged in high-risk practices and may have transmitted HIVDR to others [@pone.0088305-Ruan2]. Efforts should be made to scale up IDU services to enhance ART adherence, and harm reduction programs should be considered as an essential part of HIV treatment. Additional data is needed for understanding how the dual treatment systems for HIV and drug addiction can be successfully integrated to reduce death and transmission of blood infections.

Lastly, the association of higher CD4 cell count with virologic failure warrants further investigation. Recent WHO guideline changes and advocacy towards initiating ART treatment at higher CD4 levels (≤500 cells/mm^3^ or immediately after testing) [@pone.0088305-World1], [@pone.0088305-Cohen1] have raised concerns for adherence in asymptomatic individuals. Evidence on this issue currently remains sparse internationally and has tended to show that early treatment leads to virological and clinical benefits [@pone.0088305-Uy1], [@pone.0088305-Resistance1]. However, a large study in China has also shown that patients with higher CD4 cell counts (≥300 cells/mm^3^) at cART initiation were more likely to drop out of HIV care [@pone.0088305-Zhu1]. Here in our cohort, the rate of loss to follow-up (including transfers out of the study follow-up districts) among patients with CD4 cell counts ≥350 cells/mm^3^ and \<350 cells/mm^3^were 8.9%(5/45)and 7.7%(36/468), respectively(p = 0.77). Although the difference is not statistically significant, the sample size of patients with higher CD4 cell count is small, and more data is needed to confirm the observed relationship. In general, further studies are needed to clarify the effects of early ART initiation on adherence and attrition at short-term versus long-term treatment timescales in China.

This study has some limitations. First, due to limited geographic distribution of the sentinel sites and participant exclusion criteria, these results may not be fully representative of all of China. Second, the overall retention rate at 12 months was 87.3%, but only 79.0% in Hunan province; results should therefore be interpreted with caution. Third, due to a relatively low rate of successful HIVDR sequencing, the HIVDR rate from this study is likely lower than the true drug resistance rate. Finally, a 12-month follow up survey is relatively short for the purposes of monitoring HIVDR, and more studies with long-term monitoring is recommended to provide more objective and accurate data on viral suppression, HIVDR incidence, and optimal choices of regimen.

In sum, this HIVDR surveillance study in four sentinel sites across China demonstrates good virological and immunological outcomes at 12 months among these who initiated first-line ART treatment. However, patients infected through drug injection, who missed doses, or with higher CD4 at baseline are at increased risk for poor virological response. More data from these high-risk patients are needed to evaluate clinical outcomes and long-term effects of treatment.
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